Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-766 (nimotuzumab) with cisplatin/vinorelbine plus concurrent thoracic radiotherapy in unresectable locally advanced squamous cell lung cancer
jRCT2080222038Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing Nimotuzumab arm with Placebo arm (2 arms).
02
Drugs
nimotuzumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2080222038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222038.